Endocrine Abstracts

Objective: Immune checkpoint inhibitors (ICI) are used for treatment of non-small cell lung cancer (NSCLC) and are associated with immune-related adverse events (irAEs), especially thyroid dysfunction. Few studies found an association between thyroid dysfunction and response to Nivolumab in the NSCLC The objective of this retrospective cohort study was to investigate the association between the occurrence of thyroid dysfunction in patients treated with Nivolumab for a NSCLC an...

Background: FOP is an ultra-rare genetic disorder characterised by episodic progressive heterotopic ossification (HO) and flare-ups, causing cumulative disability and early death. FOP is diagnosed and managed by multiple specialists, including endocrinologists. There are no established disease-modifying therapies to prevent HO in FOP. Treatment guidelines for symptomatic relief of FOP have recently been published by the International Clinical Council on FOP (ICC).1<...

Background: FOP is an ultra-rare, severely disabling genetic disorder characterised by cumulative heterotopic ossification (HO), often preceded by episodic flare-ups, leading to physical disability and early death. Initial misdiagnosis can occur in ~90% of individuals leading to unnecessary, often harmful interventions. FOP is diagnosed and managed by multiple specialists, including endocrinologists.Objective: A prospective, 36-month, global natural...

Differentiated thyroid carcinoma (DTC) is viewed as an indolent disease but 5–15% of patients (pts) become refractory to RAI treatment. This is associated with poor prognosis, a 3–6 years life expectancy and accounts for approximately 200 deaths per year in Canada. There is no universal definition of rDCT and management evolves over time, with either monitoring or systemic therapy including LEN. In the Select Study on LEN in DTC, LEN provided a 19.4 month (mo) medi...